Acceleron Pharma Inc (XLRN)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

128 SIDNEY STREET CAMBRIDGE, MA 02139

Acceleron Pharma, Inc. provides pharmaceutical products. The company focuses on discovering, developing, manufacturing, and marketing of protein therapeutics for cancer and orphan diseases. Acceleron Pharma serves patients throughout the United States.

Data based on most recent fiscal year report
Market Cap2.871 Billion Shares Outstanding53.08 Million Avg Volume483.96 Thousand
1-Yr BETA vs S&P TR1.046 Current Ratio16.18 Quick Ratio16.18
View SEC Filings from XLRN instead.

View recent insider trading info

Funds Holding XLRN (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding XLRN BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

595 total shares from 2 transactions

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

POPS RICHARD F DIRECTOR AND CEO, ALKERMES PLC

  • Officer
  • Director
759,094 2020-04-02 0

ZAKRZEWSKI JOSEPH S

  • Director
30,000 2020-03-17 3

MCCOURT THOMAS A PRESIDENT

  • Officer
321,544 2020-02-27 1

SHERMAN MATTHEW L EVP & CHIEF MEDICAL OFFICER

  • Officer
36,760 2020-02-18 0

KANGO SUJAY EVP, CHIEF COMMERCIAL OFFICER

  • Officer
15,344 2020-02-13 3

GEORGE JEAN

  • Director
5,127 2020-01-22 2

MCLAUGHLIN KEVIN F SVP, CFO AND TREASURER

  • Officer
11,216 2020-01-22 5

KEARNEY TERRENCE C

  • Director
5,127 2020-01-22 1

NADER FRANCOIS

  • Director
5,127 2020-01-22 1

DABLE HABIB J CEO AND PRESIDENT

  • Officer
  • Director
89,324 2020-01-22 4

SMITH KAREN L.

  • Director
2,939 2020-01-22 1

VENESS ADAM M VP, GENERAL COUNSEL AND SEC.

  • Officer
21,161 2020-01-22 7

KANIA EDWIN M JR

  • 10% Owner
23,847 2020-01-10 0

QUISEL JOHN D EVP, CHIEF BUSINESS OFFICER

  • Officer
53,316 2020-01-02 4

BACKSTROM JAY T. EVP, RESEARCH AND DEVELOPMENT

  • Officer
0 2020-01-02 3

MALIK KEMAL

  • Director
0 2020-01-02 3

ZELDIN ROBERT K CHIEF MEDICAL OFFICER

  • Officer
0 2019-12-18 0

KUMAR RAVINDRA SVP & CHIEF SCIENTIFIC OFFICER

  • Officer
86,986 2019-09-10 2

MCGUIRE TERRANCE

  • Director
0 2019-06-01 0

MANIATIS TOM

  • Director
136,731 2019-01-25 0

CELGENE CORP /DE/

6,824,685 2019-01-18 0

ROVALDI CHRISTOPHER SVP, PROGRAM MGMT AND OPS

  • Officer
25,858 2018-04-03 0

ERTEL STEVEN D EVP & CHIEF OPERATING OFFICER

  • Officer
136,977 2017-03-02 0

KNOPF JOHN L CEO AND PRESIDENT

  • Officer
  • Director
214,084 2016-11-09 0

MCGUIRE TERRANCE

POLARIS VENTURE MANAGEMENT CO IV LLC

POLARIS VENTURE PARTNERS ENTREPRENEURS FUND IV LP

POLARIS VENTURE PARTNERS IV LP

  • Director
  • FORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNER
2,621,738 2014-06-02 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

KANGO SUJAY - Officer EVP, CHIEF COMMERCIAL OFFICER

2020-02-13 S 590 $94.09 d 15,349 15,344.00 direct yes

KANGO SUJAY - Officer EVP, CHIEF COMMERCIAL OFFICER

2020-02-13 S 5 $94.82 d 15,344 15,344.00 direct yes

Elevate your investments